The main purpose of the NOPSAD collection is to aggregate standardised jurisdictional data on the number of clients accessing pharmacotherapy for the treatment of opioid dependence, the number of prescribers participating in the delivery of pharmacotherapy treatment, and quantitative information about the prescribing sector. As such, national information on pharmacotherapy can be reported.
Collection details
|
Temporal coverage
from 30 June 2004 to 30 June 2018
|
|
Geographical coverage
National and state
|
|
Data availability
- Publications
- Summary tables published in electronic form
- Statistics
- Client specified tables on request which may be subject to data provider approval (charges apply)
- Unit records not available
|
|
Data scope
Covers the provision of opioid pharmacotherapy treatment, the practitioners who prescribe the treatment, the dosing sites who dispense the pharmacotherapy drugs, and the clients receiving the opioid pharmacotherapy treatment. The following pharmacotherapies are currently recommended for the treatment of opioid dependency:
- Methadone hydrochlorideMethadone Syrup®
- Biodone Forte ®
- BuprenorphineSubutex®
- Buprenorphine/NaloxoneSuboxone®.
|
|
Methodology
Admin data
|
|
Metadata information and data quality statement (DQS)
NOPSAD 2018 DQS
|
|
External links and information
NOPSAD 2018
Alcohol and other drug treatment services in Australia 2017–18
|
|
Contact
aod@aihw.gov.au
|